Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab

被引:45
|
作者
Genant, Harry K. [1 ,2 ]
Libanati, Cesar [3 ]
Engelke, Klaus [4 ,5 ]
Zanchetta, Jose R. [6 ]
Hoiseth, Arne [7 ]
Yuen, Chui Kin [8 ]
Stonkus, Sigtas [9 ]
Bolognese, Michael A. [10 ]
Franek, Edward [11 ,12 ]
Fuerst, Thomas [13 ]
Radcliffe, Hoi-Shen [14 ]
McClung, Michael R. [15 ]
机构
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Synarc Inc, San Francisco, CA 94105 USA
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
[4] Univ Erlangen Nurnberg, Inst Med Phys, D-91052 Erlangen, Germany
[5] Synarc Inc, Hamburg, Germany
[6] Inst Invest Metab, Buenos Aires, DF, Argentina
[7] Curato Rentgen, Oslo, Norway
[8] SIGMA Canadian Menopause Soc, Vancouver, BC V6H 1E5, Canada
[9] Klaipeda Univ Hosp, LT-92228 Klaipeda, Lithuania
[10] Bethesda Hlth Res, Bethesda, MD 20879 USA
[11] Cent Clin Hosp MSWiA, PL-02507 Warsaw, Poland
[12] Polish Acad Sci, Med Res Ctr, PL-02106 Warsaw, Poland
[13] Synarc Inc, Newark, CA 94560 USA
[14] Amgen Ltd, Cambridge CB4 OWD, England
[15] Oregon Osteoporosis Ctr, Portland, OR 97213 USA
关键词
Bone mineral density; Bone mineral content; Denosumab; Hip; Osteoporosis; Quantitative computed tomography; QUANTITATIVE COMPUTED-TOMOGRAPHY; BONE-MINERAL DENSITY; OSTEOPROTEGERIN LIGAND; NONINVASIVE ASSESSMENT; FRACTURES; TURNOVER; STRENGTH; ALENDRONATE; PHASE-2; AMG-162;
D O I
10.1016/j.bone.2013.07.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the FREEDOM study, denosumab treatment (60 mg every 6 months) decreased bone resorption, increased bone mineral density (BMD), and reduced new vertebral, nonvertebral, and hip fractures over 36 months in postmenopausal women with osteoporosis. In a subset of these women, hip quantitative computed tomography (QCT) was performed at baseline and months 12, 24, and 36. These scans were analyzed using Medical Image Analysis Framework (MIAF) software, which allowed assessment of total hip integral, trabecular, subcortical, and cortical compartments; the cortical compartment was further divided into 2 areas of interest (outer and inner cortex). This substudy reports changes in BMD and bone mineral content (BMC) from baseline and compared placebo with denosumab over 36 months of treatment (placebo N = 26; denosumab N = 36). Denosumab treatment resulted in significant improvements in total hip integral volumetric BMD (vBMD) and BMC from baseline at each time point. At month 36, the mean percentage increase from baseline in total hip integral vBMD and BMC was 6.4% and 4.8%, respectively (both p < 0.0001). These gains were accounted for by significant increases in vBMD and BMC in the trabecular, subcortical, and cortical compartments. In the placebo group, total hip integral vBMD and BMC decreased at month 36 from baseline by -1.5% and -2.6%, respectively (both p < 0.05). The differences between denosumab and placebo were also significant at months 12, 24, and 36 for integral, trabecular, subcortical, and cortical vBMD and BMC (all p < 0.05 to <0.0001). While the largest percentage differences occurred in trabecular vBMD and BMC, the largest absolute differences occurred in cortical vBMD and BMC. In summary, denosumab significantly improved both vBMD and BMC from baseline and placebo, assessed by QCT MIAF, in the integral, trabecular, subcortical, and cortical hip compartments, all of which are relevant to bone strength. (C) 2013 The Authors. Published by Elsevier Inc All rights reserved.
引用
收藏
页码:482 / 488
页数:7
相关论文
共 50 条
  • [31] Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis
    Hong, Namki
    Shin, Sungjae
    Lee, Seunghyun
    Rhee, Yumie
    OSTEOPOROSIS INTERNATIONAL, 2023, 34 (12) : 2059 - 2067
  • [32] Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis
    Namki Hong
    Sungjae Shin
    Seunghyun Lee
    Yumie Rhee
    Osteoporosis International, 2023, 34 : 2059 - 2067
  • [33] Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study
    Silverman, S. L.
    Siris, E.
    Kendler, D. L.
    Belazi, D.
    Brown, J. P.
    Gold, D. T.
    Lewiecki, E. M.
    Papaioannou, A.
    Simonelli, C.
    Ferreira, I.
    Balasubramanian, A.
    Dakin, P.
    Ho, P.
    Siddhanti, S.
    Stolshek, B.
    Recknor, C.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 (01) : 361 - 372
  • [34] Denosumab mid-term densitometric gain in postmenopausal osteoporosis women in clinical practice: comment on “Variability of denosumab densitometric response in postmenopausal osteoporosis”
    V. Torrente-Segarra
    D. Roig-Vilaseca
    Rheumatology International, 2018, 38 : 1161 - 1162
  • [35] Spatial distribution of hip cortical thickness in postmenopausal women with different osteoporotic fractures
    Ling, Ming
    Li, Xianlong
    Xu, Yueyang
    Fan, Yongqian
    ARCHIVES OF OSTEOPOROSIS, 2021, 16 (01)
  • [36] Denosumab in postmenopausal women with low bone mineral density
    Charles L. Loprinzi
    Current Oncology Reports, 2006, 8 (4) : 267 - 268
  • [37] Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
    Wensel, Terri M.
    Iranikhah, Maryam M.
    Wilborn, Teresa W.
    PHARMACOTHERAPY, 2011, 31 (05): : 510 - 523
  • [38] Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis
    Zebaze, Roger
    Libanati, Cesar
    McClung, Michael R.
    Zanchetta, Jose R.
    Kendler, David L.
    Hoiseth, Arne
    Wang, Andrea
    Ghasem-Zadeh, Ali
    Seeman, Ego
    JOURNAL OF BONE AND MINERAL RESEARCH, 2016, 31 (10) : 1827 - 1834
  • [39] Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis
    McClung, Michael R.
    Boonen, Steven
    Torring, Ove
    Roux, Christian
    Rizzoli, Rene
    Bone, Henry G.
    Benhamou, Claude-Laurent
    Lems, Willem F.
    Minisola, Salvatore
    Halse, Johan
    Hoeck, Hans C.
    Eastell, Richard
    Wang, Andrea
    Siddhanti, Suresh
    Cummings, Steven R.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (01) : 211 - 218
  • [40] Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis
    Albrecht Werner Popp
    Nadshathra Varathan
    Helene Buffat
    Christoph Senn
    Romain Perrelet
    Kurt Lippuner
    Calcified Tissue International, 2018, 103 : 50 - 54